Shots:

• MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study
• The collaboration will further explore the therapeutic potential of combination therapy- TJC4 with Keytruda across multiple tumors
• I-Mab’s TJC4 is an anti-CD47 mAb- recognizes the unique epitope on CD47- thus avoid the binding to RBCs- under clinical development in the US and has received NMPA’s IND approval in China

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Plantadoce